Patent Number: 7,820,682

Title: LPA receptor antagonist

Abstract: A compound of the general formula (I) or a non-toxic salt thereof. This compound engages in LPA receptor bonding and antagonism and is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by spinal cord neoplasm, nucleous hernia, spinal canal stenosis or diabetes, occlusion disease of lower urinary tract, inflammatory disease of lower urinary tract, polyuria), carcinoma-associated disease (solid tumor, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leucemia and carcinomatous infiltration transition), proliferative disease (disorder with aberrant angiogenesis, artery obstruction and pulmonary fibrosis), inflammation/immune system disease (psoriasis, nephropathy, hepatitis and pneumonitis symptom), disease caused by secretory dysfunction (Sjogren syndrome), brain-related disease (brain infarction, cerebral apoplexy and brain or peripheral neuropathy) or chronic disease (chronic asthma, glomerulonephritis, obesity, prostate hyperplasia, diseases caused by arteriosclerosis process, rheumatism or atopic dermatitis).

Inventors: Terakado; Masahiko (Mishima-gun, JP), Nakade; Shinji (Mishima-gun, JP), Seko; Takuya (Osaka, JP), Takaoka; Yoshikazu (Mishima-gun, JP)

Assignee: Ono Pharmaceutical Co., Ltd.

International Classification: A01N 43/90 (20060101); C07D 413/00 (20060101); C07D 403/00 (20060101); C07D 487/00 (20060101); C07D 471/00 (20060101); A61K 31/517 (20060101); A01N 43/54 (20060101); A61K 31/519 (20060101); C07D 401/00 (20060101); C07D 419/00 (20060101); C07D 417/00 (20060101)

Expiration Date: 2018-10-26 0:00:00